Season 10 · Episode 19
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
OncLive® On Air · OncLive® On Air
March 11, 20247m 19s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.